Physician profile
Milicent Young
NPI 1265415269
$2,513.16
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,003 · 2020: $392 · 2021: $52.19 · 2022: $43.96 · 2023: $22.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $408.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $277.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $233.49 | 2019-2020 | |
| Novo Nordisk INC | $212.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $197.70 | 2019-2020 | |
| Amarin Pharma, INC. | $187.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $132.92 | 2019-2023 | |
| Abbvie INC. | $127.34 | 2019-2021 | |
| Pfizer INC. | $111.91 | 2019-2020 | |
| Astellas Pharma US INC | $95.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.52 | 2019-2020 | |
| Lilly USA, LLC | $48.61 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $46.72 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $32.72 | 2019 | |
| Glaxosmithkline, LLC. | $32.44 | 2019-2020 | |
| Allergan, INC. | $26.92 | 2019-2020 | |
| Abbott Laboratories | $15.79 | 2019 | |
| Shire North American Group INC | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milicent Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.